Ehlers-Danlos Syndrome Pending FDA for treatment of vascular Ehlers-Danlos syndrome (vEDS) Mechanism of Action Theorized to provide clinical benefit for vEDS by promoting normal collagen synthesis in blood vessels; may also shift pressure load away from vessels most prone to dissection and rupture Beta1 receptor antagonist, but elicits partial agonist effects on beta2 receptors; it is also a weak alpha2 receptor antagonist Lowers blood pressure in patients with hypertension, but not in normotensive patients No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print